Aggressive fibromatosis.
Ten patients with aggressive fibromatosis of the extremities were prospectively followed for 2-6 years. Results of treatment methods were compared. Five patients underwent three-dimensional imaging with and without intravenous contrast, and the images were compared with the anatomic extent of the resected lesion. Pathologic specimens and control tissue were tested for the presence of estrogen and progesterone receptors and for expression of the c-sis oncogene and platelet-derived growth factor (PDGF), potent mitogens for fibrocytes. Wider surgical resection resulted in a lower recurrence rate, but current chemotherapeutic agents were not effective in eradicating the tumors. Intravenous contrast enhanced the lesions. Two thirds of the tumors tested had estrogen or progesterone receptors. All tumors tested had inappropriate expression of c-sis and PDGF. This inappropriate expression may be responsible for the underlying pathobiology and deregulation of control of growth in aggressive fibromatosis.
Alman
B A
BA
Department of Orthopaedics, New England Medical Center, Boston, Massachusetts.
Goldberg
M J
MJ
Naber
S P
SP
Galanopoulous
T
T
Antoniades
H N
HN
Wolfe
H J
HJ
D000328:Adult; D001132:Arm; D015152:Blotting, Northern; D002648:Child; D005260:Female; D005350:Fibroma / Q000737:chemistry* / Q000235:genetics / Q000601:surgery; D005455:Fluorescent Antibody Technique; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007231:Infant, Newborn; D007866:Leg; D008297:Male; D009857:Oncogenes; D010982:Platelet-Derived Growth Factor; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis*; D012983:Soft Tissue Neoplasms / Q000737:chemistry* / Q000235:genetics / Q000601:surgery
D010982:Platelet-Derived Growth Factor; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone